The WNT5A/ROR2 signaling pathway in pancreatic ductal adenocarcinoma (PDAC)

Lydia Remtisch

Universitätsklinikum Leipzig

Georg Wiltberger

Universitätsklinikum Aachen

Katrin Schierle

Universitätsklinikum Leipzig

Moulla Yousef

Universitätsklinikum Leipzig

René Thieme

Universitätsklinikum Leipzig

Boris Jansen-Winkeln

Universitätsklinikum Leipzig

Christian Wittekind

Universitätsklinikum Leipzig

Ines Gockel

Universitätsklinikum Leipzig

Orestis Lyros (✉ lyrosorestis@gmail.com)

Universität Leipzig Medizinische Fakultät <https://orcid.org/0000-0002-7727-7804>

Research article

Keywords: ROR2 protein, WNT5A protein, Wnt Signaling Pathway, pancreatic ductal carcinoma, survival, prognosis

Posted Date: June 24th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-34447/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

WNT5A/ROR2 signaling pathway has been shown to be involved in many human cancers. Its role in pancreatic ductal adenocarcinoma (PDAC) has not been clarified yet. The aim of this study was to determine the prognostic value of WNT5A-expression in conjunction with the ROR2-expression in the same tumor tissues of PDAC patients.

Methods

We retrospectively analyzed the expression of WNT5A and ROR2 in 117 paraffin-embedded PDAC specimens following surgical pancreatic resection by immunohistochemistry. The prognostic value of WNT5A and ROR2 was assessed using Kaplan-Meier survival curves and multivariate COX regression-models.

Results

High ROR2-expression was detected in 65.8% (77/117) of PDAC-tumors, in 28.2% (33/117) in tumor-stroma, and in 71.1% (65/90) of normal pancreatic tissue. High WNT5A-expression was found in 76.9% (90/117) of tumors, in 59.0% (69/117) of tumor-stroma, and in 83.0% (73/88) of normal pancreatic tissue. Spearman's correlation co-efficiency demonstrated weak association between ROR2- and WNT5A-expression in tumor ($r = 0.184$; $p = 0.047$), and no association in stroma ($r = 0.036$; $p = 0.699$). Multivariate analysis showed that regional lymph node invasion and differentiation were independent prognostic factors of survival, while ROR2- and WNT5A-expression not.

Conclusions

Variable expression patterns for ROR2 and WNT5A were demonstrated in PDAC and normal pancreatic tissues suggesting a role for WNT5A/ROR2 signalling pathway, not only in PDAC but also in the normal pancreatic tissue during inflammation. The lack of prognostic significance for ROR2- and WNT5A-expression in our cohort, either alone or in subgroup analysis, signifies the complexity of their role in PDAC, which is highly dependent on the different molecular receptor-ligand tissue contexts.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most fatal malignancies counting as the seventh leading cause of cancer-related death worldwide while still demonstrating the poorest prognosis of all solid tumors ^[1]. Although radical surgical R0resection, in combination with adjuvant and / or neoadjuvant treatment, remains the most promising chance of cure, high recurrence rates have been recorded ^[2], while unresectable locally advanced and disseminated disease display an unfavorable prognosis, with 5-year survival less than 9%, due to aggressive tumor biology and poor medical treatment efficacy and effectiveness ^[3]. Alternative therapeutic modalities, such as molecular therapy, which targets specific biological markers that significantly influence the lymph node metastasis and tumor progression, may add further therapeutic or prognostic benefits. Identification of such novel targets or prognostic markers requires understanding of the molecular pathways underlying the PDAC tumor biology, which still remains largely unclear.

The embryological WNT-signaling pathway is important for development and tissue homeostasis, while its dysregulation has been associated with tumorigenesis ^[4]. WNT-signaling is either canonical or non-canonical, based on the role played by the effector protein β -catenin ^[5]. In the canonical WNT-signaling, WNT-signals activate β -catenin mediated transcription of target genes that promote proliferation and differentiation ^[6]. In contrast, two distinct, non-canonical WNT-signaling pathways, the planar cell polarity (PCP) / convergent extension (CE) pathway, and the Ca^{2+} pathway (summarized in ^[7]), are activated by non-transforming WNT family members and regulate cell migration and polarity, independently of β -catenin ^[7].

WNT5A is classified as a non-transforming WNT family member which activates non-canonical WNT-signaling by interfering with receptor tyrosine kinase-like orphan receptors (ROR) [8]. ROR2 is a member of the ROR-family of receptor tyrosine kinases, acts as a receptor or co-receptor for WNT5A, and has been shown to display essential functions in developmental morphogenesis [9]. Activation of WNT5A/ROR2 signaling is reported to inhibit the canonical WNT-signaling in tumor cells, suggesting that WNT5A is a tumor suppressor [10]. In fact, absence of WNT5A-expression is associated with increased invasion and tumor progression of many carcinomas [11, 12]. However, WNT5A is speculated to also have oncogenic potential based on reports demonstrating significant WNT5A-overexpression in melanoma, lung and breast cancers [13–15]. Meanwhile, ROR2-receptor demonstrates oncogenic properties regardless the presence of a ligand [16]. Therefore, the exact function of WNT5A appears highly dependent on the receptor-context and its significance in tumor biology needs to be examined in conjunction with the ROR2-expression.

PDAC is characterized by dysregulation of the canonical WNT/ β -catenin signaling pathway, which has been associated with tumor initiation, progression and aggressive tumor biology [17–19]. The canonical WNT-signaling is reported activated in up to 65% of PanINs and increased even more frequently in invasive PDAC [20–22]. In contrast, only limited and independent reports exist so far investigating the role of non-canonical WNT5A and its ROR2-receptor in PDAC respectively. WNT5A has been shown to mediate the migration and invasion of pancreatic cancer cells via epithelial-to-mesenchymal transition (EMT) [23, 24]. On the other hand, high ROR2-expression in tumor cytoplasm or stromal cells in PDAC has been significantly associated with malignant attributes and poor patients' survival [25].

The already existing reports on WNT5A-mediated aggressive tumor phenotype and ROR2-associated poor prognosis in PDAC, stress that downstream activation of WNT5A/ROR2 signaling pathway may significantly contribute to tumor biology. However, the prognostic value of WNT5A-expression in conjunction with the ROR2-expression in PDAC has not been investigated yet, and their true clinical significance in combination remains still ambiguous. Thus, the goal of this study was to define the expression patterns and the clinical significance of both, WNT5A and ROR2, in the same pancreatic cancer tissues in an effort to show their true prognostic value and to clarify their possible biological implications in PDAC.

Materials & Methods

Patients and tissue samples

Formalin-fixed, paraffin-embedded PDAC samples following pancreatic resection in curative intent and matched, tumor-adjacent normal pancreatic specimens were collected from 117 patients with PDAC, who underwent surgery at the University Hospital of Leipzig, Germany, from 2001 to 2013. No patient received chemotherapy or radiotherapy prior to the operation. Clinical data were obtained by medical records, and follow-up survival data were gained through telephone investigation. The data included epidemiological data, such as gender and age, as well as histopathological analysis, as tumor differentiation (grading), and the pTNM-classification, lymphatic invasion (L), vascular invasion (V), perineural invasion (Pn), residual tumor (R), and UICC-Union for International Cancer Control Stage. Pathological tumor stage (pTNM) and histological differentiation were classified by GI experienced pathologist (C.W., K.S.) according to the 7th Edition of TNM staging in pancreatic cancer [26]. Data regarding adjuvant chemotherapy and distant or local relapse were also collected by follow-up. Clinical data were collected prospectively and retrospectively analyzed. This study was approved by the Ethic's Committee of the University Hospital of Leipzig, Germany (reference number: 234/14-ek).

Immunohistochemistry

Paraffin-embedded tissue samples were cut into 5 μ m slices and dried at least 6 hours at 37° C, deparaffinized and rehydrated. Endogenous peroxidase activity was blocked by 3 % hydrogen peroxide at 4° C and afterwards, non-specific bindings were blocked with 5 % normal-goat serum. The slides were incubated with the primary antibody against ROR2 (1:100, PA5-14727, Thermo Fisher Scientific, Darmstadt, Germany) and WNT5A (1:200, MA5 15511, Thermo Fisher Scientific, Darmstadt, Germany) overnight at 4° C. Horseradish-peroxidase-conjugated Affini-Pure goat anti-rabbit antibody IgG (Dianova, Hamburg, Germany) for ROR2 and anti-mouse antibody IgG (Dianova, Hamburg, Germany) for WNT5A were then applied. Immunoreactivity was

visualized with diaminobenzidine (Sigma, Taufkirchen, Germany). Positive control for ROR2 was a renal cell carcinoma sample and for WNT5A a lymph node. Negative control was fatty tissue for both (**Suppl.Figure 1A**). H&E staining facilitated the recognition of the tumor region, stroma and adjacent normal tissue in all tissue samples (**Suppl.Figure 1B**).

Evaluation of immunohistochemistry reaction

The slides were evaluated by three independent reviewers (L.R., O.L., G.W.). The evaluation of expression of ROR2 and WNT5A was based on the percentage of positive cells [0 % (no positive cells), 35 %, 65 % and 100 % (all cells positive)] and their intensity [0 (no staining), 1 (weak intensity), 2 (moderate intensity) and 3 (strong intensity)]. For each tissue sample, the percentage of cells stained at certain intensity was determined and multiplied by the intensity score to generate an intensity percentage score, which ranged from 0 to 300, as described previously ^[25]. Expression in the tumor, stroma and normal tissue were analyzed. The cut-off value for distinguishing positive and negative expression was set at 65 based on consensus of the three independent experts.

Statistical Analysis

Biomedical statistician performed the statistical review of the study. A χ^2 -test was used to test the correlation of ROR2- and WNT5A-expression with clinicopathological variables. Overall survival (OS) was calculated from day of first surgery until death or end of follow up using the Kaplan-Meier method, and the log-rank test was used for survival analysis. Cox-regression model was used to perform multivariate analysis. Correlation between ROR2 and WNT5A expression was tested using spearman correlation. For all tests, the significance level for statistical analyses was set at $p < 0.05$. All data were analyzed using IBM[®] SPSS[®] Statistics (Version 24.0.0, IBM[®], Armonk, USA).

Results

Patient Cohort

In total, tissue samples were collected from 117 patients with PDAC, who underwent pancreatic resection at the University Hospital of Leipzig, Germany, from 2001 to 2013. At the time of surgery, patients' ages ranged from 40 to 84 years, with a median age of 66 years. There were 45 females (38.5%) and 72 males (61.5%). None of the patients had received neoadjuvant treatment prior to surgery. The surgical procedures included Kausch-Wipple operations in 53 patients, pylorus-preserving pancreaticoduodenectomy (PPPD) in 50 patients, left pancreatectomy in 12 patients, and total pancreatectomy in 2 patients. In 9 patients with intraoperatively detected oligometastasis (M1), the operation was still performed along with removal of the oligometastatic site due to younger age (5 patients with singular liver metastasis and 4 patients with intraaortocaval lymph node metastasis). According to the decision of the interdisciplinary tumor board, based on the final pathology report, 50 (43%) patients received adjuvant chemotherapy. The median follow-up reached 100 months (8 years). The median overall survival was 19.5 months with a 95% confidence interval [CI] of 14.4 – 24.6 months (**Figure 1**). Patients who received adjuvant chemotherapy demonstrated an improved overall survival. The 5-years survival rate following curative resection reached 16%. These findings correlate with the statistics reported in patients able to undergo a successful curative resection, in which median survival time ranges from 12-19 months, and the 5-year survival rate is 15-20 % ^[27]. Patients' characteristics are summarized in **Table 1**.

Expression of ROR2 and WNT5A in PDAC

To analyse the expression of ROR2 and WNT5A in PDAC, we performed immunohistochemistry in all 117 tumor samples along with the adjacent normal tissue, if available (n=90 in ROR2 and n=88 in WNT5A). Positive staining of ROR2 and WNT5A were primarily localized in the cytoplasm of tumor cells, in the stroma and in normal pancreatic tissue. For statistical analysis, we dichotomized the expression of both, ROR2 and WNT5A, at a cut-off value of 65 based on tabular analysis. Tissues with protein staining of 65 or less were considered negative, otherwise they were labelled as positive. High ROR2- expression was found in 65.8 % (77/117) of tumors, in 28.2 % (33/117) in tumor-stroma, and in 71.1 % (65/90) of normal pancreatic tissue. The expression in tumor cells was significantly higher than in stromal tissue ($p < 0.001$). High WNT5A-expression was found in 76.9 % (90/117) of tumors, 59.0 % (69/117) in stroma, and 83.0 % (73/88) in normal tissue. Similarly, expression in tumor cells was

significantly higher than in stromal tissue ($p < 0.001$). Representative immunohistochemical staining for ROR2 and WNT5A in PDAC tissues is shown in **Figure 2A** and **Figure 2B** respectively. Calculation of Spearman's correlation coefficient demonstrated weak association between ROR2- and WNT5A-expression in the tumor ($r = 0.184$; $p = 0.047$) and no association in the stroma ($r = 0.036$; $p = 0.699$) (data not shown).

Association between ROR2- and WNT5A-expression patterns with clinicopathological parameters

To further elucidate the concomitant role of ROR2 and WNT5A in PDAC, we analysed the associations between their expression patterns and major clinicopathological parameters. As shown in **Tables 2 and 3**, no significant associations were detected between the positive ROR2- and WNT5A-expression in all three investigated tissue types (tumor, stroma and normal tissue) with any clinical parameter, respectively.

Survival analysis

Univariate analysis showed differences for overall survival between the following groups: differentiation grade (G), tumor depth of invasion (pT), regional lymph node metastasis (pN), lymphatic (L) and vessel invasion (V) along with recurrence and metastasis (**Table 4**). No significant association with overall survival was found for high expression in tumor, stroma and normal pancreatic tissue of either ROR2 (**Figure 3A**) or WNT5A (**Figure 3B**). Multivariate analysis identified the regional lymph node invasion and the grading to be independent prognostic factors of survival. Patients with lymph node invasion showed a Hazard Ratio (HR) of 3.00, thus a 3 times increased risk to cancer related death than patients without lymph node invasion. Poorly differentiated tumors (G3) showed a 1.6 higher risk to cancer related death than tumors of G1 or G2 grading. ROR2- and WNT5A-levels of expression could not be identified as independent prognostic parameters. Further subgroup analysis of possible combinations of ROR2- and WNT5A-expression patterns also failed to demonstrate significant differences in overall survival (**Figure 4A**). Finally, in order to evaluate whether ROR2- and WNT5A-expression patterns may influence response to adjuvant chemotherapy, we performed subgroup analyses only for patients who had received adjuvant chemotherapy ($n = 50$). In this subgroup analysis, both ROR2- and WNT5A-expression failed to demonstrate any prognostic value in the setting of adjuvant chemotherapy (**Figure 4B & 4C**).

Discussion

To our knowledge, this is the first study to analyze simultaneously the prognostic value of ROR2- and WNT5A-expression patterns in PDAC patients, in an effort to reveal the true role of the non-canonical ROR2/WNT5A signaling pathway in this malignancy. We demonstrated variable expression patterns for ROR2 and WNT5A, in tumor, stroma and normal pancreatic tissues, which, however, failed to demonstrate any type of correlation to each other. High WNT5A-expression was found in 76.9% of PDAC tissues. This is in accordance with the previous study displaying a positive WNT5A-expression in 81.3% of pancreatic cancer tissues [24]. On the other hand, the positive expression rate of ROR2 in our study was higher, up to 65% of the examined PDCA tissues, compared to the previous reported rate of 45.7% [25]. Noteworthy, we demonstrated elevated expression rates for ROR2 and WNT5A also in the adjacent normal pancreatic tissue, up to 71% and 83% respectively. Regarding their clinical significance, expression patterns of ROR2 and WNT5A in our analysis failed to correlate with clinicopathological parameters or to demonstrate a prognostic significance in survival, even in the subgroup analysis. In contrast, regional lymph node invasion and differentiation levels were defined as independent prognostic factors of survival.

ROR2 is a co-receptor for WNT5A and exerts its function predominantly via the non-canonical WNT-signaling [9]. On the other hand, WNT5A functions highly dependent on the receptor context, and its role in tumor biology is highly influenced by the presence of the ROR2-receptor. Therefore, the prognostic significance of ROR2 should be evaluated only in conjunction with WNT5A and vice versa. The already reported high expression rates of WNT5A and ROR2 in PDAC along with their association with aggressive tumor phenotype and poor prognosis has been shown in independent studies, respectively [24, 25]. These findings undelay the activation of the WNT5A/ROR2 signaling pathway, which may contribute to the PDAC tumor promotion. However, WNT5A-mediated activation of the ROR2-receptor is claimed to mediate inhibition of the canonical Wnt/ β -catenin signalling [28], whose activation has also been strongly associated with PDAC carcinogenesis and tumor progression [18, 22]. Therefore,

expression patterns indicative of WNT5A/ROR2 signaling activation, such as double positive cancers (ROR2+/WNT5A+) should be expected to be associated with better prognosis, rather than poorer as reported previously. In an effort to clarify this uncertain background, our study aimed to evaluate the ROR2- and WNT5A-expressions in combination in the same PDAC tissues and to facilitate a more confident conclusion on their prognostic value. Although high expression rates of ROR2 and WNT5A were demonstrated, in 65% and 76.9% of the PDAC tissues respectively, our study failed to confirm any association with clinico-pathological parameters or to demonstrate a prognostic impact for the expression of both.

Previous reports support an oncogenic role for ROR2 and WNT5A positive expression in PDAC [24,25], which however could not be confirmed further in our study. The lack of prognostic significance can be attributed to the complexity of the ROR2 and WNT5A functions, which are highly dependent on the receptor-ligand context and vary under different molecular conditions. Even the study of Bo et. al [24], which supported that WNT5A-upregulation promotes EMT and metastasis in pancreatic cancer via activation of the canonical WNT/ β -catenin signalling and independently of ROR2 receptor, could not finally demonstrate a prognostic significance for WNT5A-expression. On the other hand, Huang and colleagues recently supported that high ROR2-expression is associated with poor prognosis without, however, to evaluate WNT5A-expression patterns or other downstream molecules of the ROR2 receptor in their cohort [25]. Regarding other malignancies, several reports have attempted to investigate the prognostic values of ROR2 and WNT5A in combination, supporting the viewpoint that double positive cancers (ROR2+/WNT5A+) might have significantly worse survival than those with double negative cancers (ROR2-/WNT5A-) [29–34], while other studies suggest independent roles for WNT5A as tumor-suppressor and for ROR2-receptor as mediator of WNT5A-independent tumor-promotion [35,36,10]. This variety in WNT5A and ROR2 molecular functions in regard to tumor progression, surely reflects the differences in the receptor-ligand context or cell context of cancer cells even in PDAC and can in part explain the lack of significance, even in the subgroup analysis.

An interesting finding in our study is the high rates of positive ROR2- and WNT5A-expression in the normal pancreatic tissues. In adult tissues, expression levels of WNT5A and ROR2 are in general decreased [37]. Thus, the majority of oncological reports tend to speculate the potential of ROR2 and WNT5A as therapeutic targets based on their differential expressions within human malignancies and on the low to absent expression in normal tissues [38]. However, the expression in normal tissues is often neglected in reporting. Therefore, the positive expression of WNT5A and ROR2 in the adjacent normal pancreatic tissue as found here, signifies their role in pancreatic tissue physiology and inflammation. The roles of WNT5A-ROR2 axis in normal cells has been demonstrated, involving diverse cellular functions, including cell polarization, migration and stemness [37]. Such prominent cellular processes in the adjacent to PDAC normal pancreatic tissue may dictate the tumor microenvironment in favour of tumor progression and merit further investigation.

This study has some limitations. Due to the retrospective character of the study, the current findings may not be applicable to the general population. Larger prospective studies are required to verify or to exclude the prognostic value of WNT5A and ROR2 in PDAC. In addition, we utilized immunohistochemistry (IHC), which only assesses protein expression of WNT5A and ROR2 in pancreatic tissues and as such provide rather limited information on the functional level without allowing conclusions on their molecular interactions. Lastly, additional methods are needed to confirm the ROR2 and WNT5A expression levels in PDAC cells, since IHC data are semiquantitative.

In conclusion, in this study, we examine for the first time the synergistic effect of ROR2 and WNT5A expression patterns on the prognosis of patients with PDAC. We report variable expression patterns for ROR2 and WNT5A in PDAC, stroma and adjacent normal pancreatic tissues, suggesting a role for non-canonical WNT5A/ROR2 signaling pathway in the pancreatic tissue physiology and PDAC tumor biology. However, both markers failed to demonstrate prognostic significance, either alone or in the subgroup analysis, indicating the complexity of their role in PDAC, which appears highly dependent on the different molecular receptor-ligand tissue contexts. The correlation between ROR2 and WNT5A in PDAC merits further evaluation in larger sample size studies along with *in vitro* studies in order to clarify the mechanism of interaction in tumor progression and pancreatic pathophysiology.

Abbreviations

PDAC = pancreatic ductal adenocarcinoma, ROR = receptor tyrosine kinase-like orphan receptors,

Declarations

Ethics approval and consent to participate: This study was approved by the Ethic's Committee of the University Hospital of Leipzig, Germany (reference number: 234/14-ek).

Consent for publication: not applicable

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: This work was supported by the Clinician Scientist Scholarship program of the Faculty of Medicine, University of Leipzig, Germany for Orestis Lyros.

Authors' contributions: Remtisch L performed the experiments and analysis of data, Lyros O conceptualized, designed and coordinated the study, performed analysis and interpretation of data and wrote the paper; Wiltberger G, Katrin Schierle K. and Thieme R performed analysis and interpretation of data; Moulla Y, Boris Jansen-Winkel B, Wittekind C and Gockel I performed interpretation of data and critically revised the manuscript.

Acknowledgements: The authors would like to thank Franziska Rolfs and Ulrike Schmiedek for their excellent technical support.

References

- 1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7–30 [PMID: 29313949 DOI: 10.3322/caac.21442]
- 2 **Vincent A**, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *The Lancet* 2011; **378**: 607–620 [DOI: 10.1016/S0140-6736(10)62307-0]
- 3 **Oberstein PE**, Olive KP. Pancreatic cancer: why is it so hard to treat? *Therap Adv Gastroenterol* 2013; **6**: 321–337 [PMID: 23814611 DOI: 10.1177/1756283X13478680]
- 4 **Lee JM**, Kim IS, Kim H, Lee JS, Kim K, Yim HY, Jeong J, Kim JH, Kim J-Y, Lee H, Seo S-B, Kim H, Rosenfeld MG, Kim KI, Baek SH. ROR α attenuates Wnt/ β -catenin signaling by PKC α -dependent phosphorylation in colon cancer. *Mol Cell* 2010; **37**: 183–195 [PMID: 20122401 DOI: 10.1016/j.molcel.2009.12.022]
- 5 **Zhan T**, Rindtorff N, Boutros M. Wnt signaling in cancer. *Oncogene* 2017; **36**: 1461–1473 [PMID: 27617575 DOI: 10.1038/onc.2016.304]
- 6 **Aoki M**, Hecht A, Kruse U, Kemler R, Vogt PK. Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. *Proc Natl Acad Sci U S A* 1999; **96**: 139–144 [PMID: 9874785]
- 7 **Moon RT**, Kohn AD, Ferrari GV de, Kaykas A. WNT and β -catenin signalling: diseases and therapies. *Nat Rev Genet* 2004; **5**: 691–701 [PMID: 15372092 DOI: 10.1038/nrg1427]
- 8 **Kikuchi A**, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. *Acta Physiol (Oxf)* 2012; **204**: 17–33 [PMID: 21518267 DOI: 10.1111/j.1748-1716.2011.02294.x]
- 9 **Oishi I**, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada G, Schwabe GC, Mundlos S, Shibuya K, Takada A, Minami Y. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. *Genes Cells* 2003; **(8)**: 645–654

- 10 **KremenevskajaN**, Wasielewski R von, Rao AS, Schofl C, Andersson T, Brabant G. Wnt-5a has tumor suppressor activity in thyroid carcinoma. *Oncogene* 2005; **24**: 2144–2154 [PMID: 15735754 DOI: 10.1038/sj.onc.1208370]
- 11 **BlancE**, Le Roux G, Benard J, Raguenez G. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. *Oncogene* 2005; **24**: 1277–1283 [PMID: 15592517 DOI: 10.1038/sj.onc.1208255]
- 12 **JönssonM**, Dejmek J, Bendahl P-O, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. *Cancer Res* 2002; **62**: 409–416 [PMID: 11809689]
- 13 **DejmekJ**. Expression and Signaling Activity of Wnt5a/Discoidin Domain Receptor-1 and Syk Plays Distinct but Decisive Roles in Breast Cancer Patient Survival. *Cancer Res* 2005; (**11**): 520–528
- 14 **IozzoRV**, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5A in human malignancy. *Cancer Res* 1995; **55**: 3495–3499 [PMID: 7627953]
- 15 **WeeraratnaAT**, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. *Cancer Cell* 2002; **1**: 279–288 [PMID: 12086864]
- 16 **WrightTM**, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. *Oncogene* 2009; **28**: 2513–2523 [PMID: 19448672 DOI: 10.1038/onc.2009.116]
- 17 **WhiteBD**, Chien AJ, Dawson DW. Dysregulation of Wnt/ β -catenin signaling in gastrointestinal cancers. *Gastroenterology* 2012; **142**: 219–232 [PMID: 22155636 DOI: 10.1053/j.gastro.2011.12.001]
- 18 **ZhangY**, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M, Di Pasca Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. *Cancer Res* 2013; **73**: 4909–4922 [PMID: 23761328 DOI: 10.1158/0008-5472.CAN-12-4384]
- 19 **MorrisJP, 4th.**, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat Rev Cancer* 2010; **10**: 683–695 [PMID: 20814421 DOI: 10.1038/nrc2899]
- 20 **Di Pasca MaglianoM**, Biankin AV, Heiser PW, Cano DA, Gutierrez PJA, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM, Sutherland RL, Dlugosz A, Rustgi AK, Hebrok M. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. *PLoS One* 2007; **2**: e1155 [PMID: 17982507 DOI: 10.1371/journal.pone.0001155]
- 21 **WangL**, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. *Cancer Cell* 2009; **15**: 207–219 [PMID: 19249679 DOI: 10.1016/j.ccr.2009.01.018]
- 22 **ZengG**, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SPS. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. *Neoplasia* 2006; **8**: 279–289 [PMID: 16756720 DOI: 10.1593/neo.05607]
- 23 **RipkaS**, Konig A, Buchholz M, Wagner M, Sipos B, Kloppel G, Downward J, Gress T, Michl P. WNT5A–target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. *Carcinogenesis* 2007; **28**: 1178–1187 [PMID: 17227781 DOI: 10.1093/carcin/bgl255]
- 24 **BoH**, Zhang S, Gao L, Chen Y, Zhang J, Chang X, Zhu M. Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. *BMC Cancer* 2013; **13**: 496 [PMID: 24156409 DOI: 10.1186/1471-2407-13-496]
- 25 **HuangJ**, Fan X, Wang X, Lu Y, Zhu H, Wang W, Zhang S, Wang Z. High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. *Sci Rep* 2015; **5**: 12991 [PMID: 26259918]

- 26 **Sobin LH**, Gospodarowicz MK, Wittekind C (eds.) TNM Classification of Malignant Tumours, 7th edition (2010), Wiley-Blackwell, Oxford
- 27 **DistlerM**, Rückert F, Hunger M, Kersting S, Pilarsky C, Saeger H-D, Grützmann R. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. *BMC Surg* 2013; **13**: 12 [PMID: 23607915 DOI: 10.1186/1471-2482-13-12]
- 28 **MikelsAJ**, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. *PLoS Biol* 2006; **4**: e115 [PMID: 16602827 DOI: 10.1371/journal.pbio.0040115]
- 29 **LuC**, Wang X, Zhu H, Feng J, Ni S, Huang J. Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer. *Oncotarget* 2015; **6**: 24912–24921 [PMID: 26305508 DOI: 10.18632/oncotarget.4701]
- 30 **EdrisB**, Espinosa I, Muhlenberg T, Mikels A, Lee C-H, Steigen SE, Zhu S, Montgomery KD, Lazar AJF, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. *J Pathol* 2012; **227**: 223–233 [PMID: 22294416 DOI: 10.1002/path.3986]
- 31 **KobayashiM**, Shibuya Y, Takeuchi J, Murata M, Suzuki H, Yokoo S, Umeda M, Minami Y, Komori T. Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009; **107**: 398–406 [PMID: 19217015 DOI: 10.1016/j.tripleo.2008.08.018]
- 32 **Fernandez-CoboM**, Zammarchi F, Mandeli J, Holland JF, Pogo BGT. Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells. *Oncol Rep* 2007; **17**: 903–907 [PMID: 17342334]
- 33 **LeeSE**, Lim SD, Kang SY, Suh SB, Suh Y-L. Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma. *Brain Pathol* 2013; **23**: 445–453 [PMID: 23278988 DOI: 10.1111/bpa.12017]
- 34 **LuB-J**, Wang Y-Q, Wei X-J, Rong L-Q, Wei D, Yan C-M, Wang D-J, Sun J-Y. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. *Mol Med Rep* 2012; **5**: 1033–1036 [PMID: 22293903 DOI: 10.3892/mmr.2012.772]
- 35 **LyrosO**, Nie L, Moore T, Medda R, Otterson M, Behmaram B, Mackinnon A, Gockel I, Shaker R, Rafiee P. Dysregulation of WNT5A/ROR2 Signaling Characterizes the Progression of Barrett-Associated Esophageal Adenocarcinoma. *Mol Cancer Res* 2016; **14**: 647–659 [PMID: 27084312 DOI: 10.1158/1541-7786.MCR-15-0484]
- 36 **YamamotoH**, Oue N, Sato A, Hasegawa Y, Matsubara A, Yasui W, Kikuchi A. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. *Oncogene* 2010; **29**: 2036–2046 [PMID: 20101234 DOI: 10.1038/onc.2009.496]
- 37 **ZhouY**, Kipps TJ, Zhang S. Wnt5a Signaling in Normal and Cancer Stem Cells. *Stem Cells Int* 2017; **2017**: 5295286 [PMID: 28491097 DOI: 10.1155/2017/5295286]
- 38 **RebagayG**, Yan S, Liu C, Cheung N-K. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. *Front Oncol* 2012; **2**: 34 [PMID: 22655270 DOI: 10.3389/fonc.2012.00034]

Tables

Table 1: Clinical Characteristics of patient cohort

Variable	Total No.	%
Total	117	100
Age		
Median	66	
Min./Max.	40-84	
Sex		
Female	45	38.5
Male	72	61.5
TNM		
pT		
pT1	4	3.4
pT2	20	17.1
pT3	90	76.9
pT4	3	2.6
pN		
pN0	35	29.9
pN1	82	70.1
M		
M0	40	34.2
M1	9	7.7
Unknown	68	-
Lymphvessel invasion (L)		
L0	17	14.5
L1	91	77.8
Unknown	9	-
Vascular invasion (V)		
V0	75	64.1
V1	30	25.6
Unknown	12	-
Perineural invasion (Pn)		
Pn0	15	12.8
Pn1	78	66.7
Unknown	24	-

Resection margin (R)		
R0	91	77.8
R1	24	20.5
R2	2	1.7
Grading (G)		
G1	1	0.9
G2	55	47.0
G3	61	52.1
G4	0	0
UICC 7.0		
IA	1	0.9
IB	5	4.3
IIA	27	23.1
IIB	70	59.8
III	4	3.4
IV	10	8.5
Relapse Metastasis		
Yes	41	35.0
No	76	65.0
Local Relapse		
Yes	22	18.8
No	95	81.2
Chemotherapy		
Yes	50	42.7
No	67	57.3

Table 2: Association of ROR2-expression with clinicopathological parameters in PDAC *p<0.05

ROR2	Tumor			Stroma			Normal Tissue		
	Expression		P value	Expression		P value	Expression		P value
	negative	positive		negative	positive		negative	positive	
	(%)	(%)		(%)	(%)		(%)	(%)	
Total No.	117	40	77	84	33	90	26	64	
Age			0.491			0.756			0.609
≤60 years	40	12(30.0)	28(70.0)	28(70.0)	12(30.0)	31	10(32.3)	21(67.7)	
>60 years	77	28(36.4)	49(63.6)	56(72.7)	21(27.3)	59	16(27.1)	43(72.9)	
Sex			0.878			0.897			0.849
Female	45	15(33.3)	30(66.7)	32(71.1)	13(28.9)	36	10(27.8)	26(72.2)	
Male	72	25(34.7)	47(65.3)	52(72.2)	20(27.8)	54	16(29.6)	38(70.4)	
pT			0.561			0.907			0.059
pT1 & pT2	24	7(29.2)	17(70.8)	17(70.8)	7(29.2)	14	1(7.1)	13(92.9)	
pT3 & pT4	93	33(35.5)	60(64.5)	67(72.0)	26(28.0)	76	25(32.9)	51(67.1)	
pN			0.660			0.954			0.451
N0	35	13(37.1)	22(62.9)	25(71.4)	10(28.6)	27	6(22.2)	21(77.8)	
N1	82	27(32.9)	55(67.1)	59(72.0)	23(28.0)	63	20(31.7)	43(68.3)	
M			0.273			1.000			0.663
M0	40	23(57.5)	17(42.5)	34(85.0)	6(15.0)	32	12(37.5)	20(62.5)	
M1	9	3(33.3)	6(66.7)	8(88.9)	1(11.1)	6	3(50.0)	3(50.0)	
Unknown	68					52			
L			0.939			0.772			1.000
L0	17	6(35.3)	11(64.7)	12(70.6)	5(29.4)	13	4(30.8)	9(69.2)	
L1	91	33(36.3)	58(63.7)	67(79.0)	24(29.0)	71	22(31.0)	49(69.0)	
Unknown	9					6			
V			0.609			0.724			0.225
V0	75	29(38.7)	46(61.3)	55(73.3)	20(26.7)	62	17(27.4)	45(72.6)	
V1	30	10(33.3)	20(66.7)	23(76.7)	7(23.3)	19	8(42.1)	11(57.9)	
Unknown	12					9			
Pn			0.836			0.752			0.262
Pn0	15	6(40.0)	9(60.0)	12(80.0)	3(20.0)	10	1(10.0)	9(90.0)	
Pn1	78	29(37.2)	49(62.8)	57(73.1)	21(26.9)	62	20(32.3)	42(67.7)	
Unknown	24					18			
Grading			0.403			0.744			0.508
G1 & G2	56	17(30.4)	39(69.6)	41(73.2)	15(26.8)	43	11(25.6)	33(74.4)	

G3	61	23(37.7)	38(62.3)	43(70.5)	18(29.5)	47	15(31.9)	32(68.1)
UICC 7.0			0.553			0.918		0.940
IIA	27	11(40.7)	16(59.3)	19(70.4)	8(29.6)	20	6(30.0)	14(70.0)
IIB	70	24(34.3)	46(63.9)	50(71.4)	20(28.9)	55	17(30.9)	38(69.1)
Other	20					15		
Relapse metastasis			0.688			0.808		0.394
Yes	41	15(36.6)	26(63.4)	30(73.2)	11(26.8)	32	11(34.4)	21(65.6)
No	76	25(32.9)	51(67.1)	54(71.1)	22(28.9)	58	15(25.9)	43(74.1)
Local relapse			0.216			0.914		0.559
Yes	22	10(45.5)	12(54.5)	16(72.7)	6(27.3)	17	6(35.3)	11(64.7)
No	95	30(31.6)	65(68.4)	68(71.6)	27(28.4)	73	20(27.4)	53(72.6)

Table 3: Association of WNT5A-expression with clinicopathological parameters in PDAC *p<0.05

WNT5A	Tumor			Stroma			Normal Tissue		
	Expression		P value	Expression		P value	Expression		P value
	negative (%)	positive (%)		negative (%)	positive (%)		negative (%)	positive (%)	
Total No.	117	27	90	48	69	88	15	73	
Age									
			0.200			0.815			0.596
≤60 years	40	12(30.0)	28(70.0)	17(42.5)	23(57.5)	30	6(20.0)	24(80.0)	
>60 years	77	15(19.5)	62(80.5)	31(40.3)	46(59.7)	58	9(15.5)	49(84.5)	
Sex									
			0.862			0.327			0.421
Female	45	10(22.2)	35(77.8)	21(46.7)	24(53.3)	33	7(21.2)	26(78.8)	
Male	72	17(23.6)	55(76.4)	27(37.5)	45(62.5)	55	8(14.5)	47(85.5)	
pT									
			0.060			0.142			0.700
pT1 & pT2	24	9(37.5)	15(62.5)	13(54.2)	11(45.8)	14	3(21.4)	11(78.6)	
pT3 & pT4	93	18(19.4)	75(80.6)	35(37.6)	58(62.4)	74	12(16.2)	62(83.8)	
pN									
			0.658			0.333			0.538
pN0	35	9(25.7)	26(74.3)	12(34.3)	23(65.7)	26	3(11.5)	23(88.5)	
pN1	82	18(22.0)	64(78.0)	36(43.9)	46(56.1)	62	12(19.4)	50(80.6)	
pM									
			0.440			1.000			1.000
pM0	40	10(25.0)	30(75.0)	15(37.5)	25(62.5)	31	4(12.9)	27(87.1)	
pM1	9	1(11.1)	8(88.9)	3(33.3)	6(66.7)	6	1(16.7)	5(83.3)	
Unknown	68					51			
L									
			0.235			0.304			0.698
L0	17	6(35.3)	11(64.7)	9(52.9)	8(47.1)	13	3(23.1)	10(76.9)	
L1	91	20(22.0)	71(78.0)	36(39.6)	55(60.4)	69	12(17.4)	57(82.6)	
Unknown	9					6			
V									
			0.942			0.618			1.000
V0	75	18(24.0)	57(76.0)	31(41.3)	44(58.7)	61	11(18.0)	50(82.0)	
V1	30	7(23.3)	23(76.7)	14(46.7)	16(53.3)	119	3(15.8)	16(84.2)	
Unknown	12					8			
Pn									
			0.499			0.122			1.000
Pn0	15	4(26.7)	11(73.3)	9(60.0)	6(40.0)	11	1(9.1)	10(90.9)	
Pn1	78	15(19.2)	63(80.8)	30(38.5)	48(61.5)	60	10(16.7)	50(83.3)	
Unknown	24					17			
Grading									
			0.177			0.130			0.995
G1 & G2	56	16(28.6)	40(71.4)	27(48.2)	29(51.8)	41	7(17.1)	34(82.9)	

G3	61	11(18.0)	50(82.0)	21(34.4)	40(65.6)	47	8(17.0)	39(83.0)
UICC 7.0			0.751		0.075			0.727
IIA	27	5(18.5)	22(81.5)	7(25.9)	20(74.1)	19	2(10.5)	17(89.5)
IIB	70	15(21.4)	55(78.4)	32(45.7)	38(54.3)	54	10(18.5)	44(81.5)
Other	20					15		
Relapse metastasis			0.111		0.132			0.042
Yes	41	6(14.6)	35(85.4)	13(31.7)	28(68.3)	32	2(6.2)	30(93.8)
No	76	21(27.6)	55(72.4)	35(46.1)	41(53.9)	56	13(23.2)	43(76.8)
Local relapse			0.966		0.990			0.726
Yes	22	5(22.7)	17(77.3)	9(40.9)	13(59.1)	18	2(11.8)	15(88.2)
No	95	22(23.2)	73(76.8)	39(41.1)	56(58.9)	71	13(18.3)	58(81.7)

Table 4: Univariate and multivariate analysis of prognostic factors for 5-year survival in PDAC *p<0.05

Variable	Univariate analysis			Multivariate analysis		
	HR	95% KI	P-value	HR	95% KI	P-Value
ROR2 Tumor	0,78	0,50-1,20	0,261	0,75	0,45-1,25	0,272
Negativ (ref) vs. Positiv						
WNT5A Tumor	0,95	0,57-1,56	0,829	0,89	0,53-1,49	0,648
Negativ (ref) vs. Positiv						
ROR2 Stroma	0,95	0,60-1,50	0,820	0,83	0,49-1,42	0,500
Negativ (ref) vs. Positiv						
WNT5A Stroma	0,83	0,54-1,28	0,412	0,86	0,55-1,35	0,517
Negativ (ref) vs. Positiv						
Geschlecht	1,13	0,72-1,61	0,597			
Weiblich (ref) vs. Männlich						
Alter	1,28	0,81-2,00	0,288			
≤ 60 (ref) vs > 60						
Grading	1,84	1,18-2,85	0,007	1,58	1,00-2,50	0,050
G1 & G2 (ref) vs. G3						
pT	1,79	1,05-3,05	0,033	1,23	0,70-2,18	0,474
pT1&pT2 (ref) vs. pT3&pT4						
pN	3,16	1,87-5,33	<0,001	3,00	1,70-5,28	<0,001
N0 (ref) vs. N1						
pM	1,70	0,79-3,67	0,172			
M0 (ref) vs. M1						
L	2,47	1,22-4,97	0,012			
L0 (ref) vs. L1						
V	1,90	1,15-3,02	0,011			
V0 (ref) vs. V1						
Pn	0,93	0,50-1,73	0,815			
Pn0 (ref) vs. Pn1						
Recurrance Metastasis	0,47	0,30-0,74	0,001			
ja (ref) vs. nein						
Local Recurrance	0,75	0,45-1,23	0,248			

Figures

Figure 4

Figure 1

Subgroup analysis of overall survival in PDAC patients with different combinations of ROR2- and WNT5A-expression patterns (A) and in PDAC patients, who had received adjuvant chemotherapy with ROR2 negative and positive expression (B) or WNT5A negative and positive expression (C).

Figure 3

Figure 3

Figure 2

Survival analysis of PDAC patients with Kaplan-Meier method and log-rank test. Overall survival rates in patients with ROR2 negative and positive expression (A) and WNT5A negative and positive expression (B) in tumor cells, stroma and adjacent normal tissue.

Figure 2

Figure 2

Figure 3

Representative pattern of ROR2-expression (A) and WNT5A-expression (B) in PDAC, stroma and adjacent normal pancreatic tissue, as determined by IHC. Bar 200 μ m

Figure 1

Figure 4

Overall survival of the patient cohort (median survival: 19,5 months)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureAdditionalWnt5aROR2ManuskriptRemtischetal.jpg](#)